Ümran Toru1, Ceylan Ayada2, Osman Genç2, Server Şahin3, Özlem Arık4, Murat Acat5, İsmet Bulut6, Erdoğan Çetinkaya7. 1. Department of Chest Diseases, Dumlupınar University Faculty of Medicine Kütahya 43100, Turkey. 2. Department of Physiology, Dumlupınar University Faculty of Medicine Kütahya 43100, Turkey. 3. Department of Medical Biology, Dumlupınar University Faculty of Medicine Kütahya 43100, Turkey. 4. Department of Biostatistics, Dumlupınar University Faculty of Medicine Kütahya 43100, Turkey. 5. Department of Chest Diseases, Karabük University Faculty of Medicine Karabük 78200, Turkey. 6. Department of Adult Immunology and Allergy, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital İstanbul 34844, Turkey. 7. Department of Chest Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital İstanbul 34020, Turkey.
Abstract
BACKGROUND & AIM: Asthma represents chronic inflammation of the airways and is associated with bronchial hyperresponsiveness and reversible airway obstruction. A novel adipokine visfatin and an appetite-modulating hormone ghrelin play a role in several diseases related with inflammation. Although visfatin is a pro-inflammatory adipokine, ghrelin mainly exerts anti-inflammatory effects. However, very little is known about the role of visfatin and ghrelin in asthma. In the present study, we aimed to investigate the role of visfatin and ghrelin in asthma by evaluating their serum levels in asthmatic patients. MATERIALS AND METHODS: This study was performed on 27 asthma and 23 healthy controls. Blood samples were collected in tubes without EDTA. Serum levels of visfatin and ghrelin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program and differences were considered statistically significant at p < 0.05. RESULTS: Serum levels of visfatin and ghrelin were significantly higher in asthma group (respectively; p = 0.001, p = 0.002). CONCLUSION: While visfatin has a pro-inflammatory role, ghrelin exerts an anti-inflammatory effect in asthma. Therefore, visfatin can be a forthcoming biomarker and ghrelin may be a new anti-inflammatory drug target to diagnose and treat asthmatic patients.
BACKGROUND & AIM: Asthma represents chronic inflammation of the airways and is associated with bronchial hyperresponsiveness and reversible airway obstruction. A novel adipokine visfatin and an appetite-modulating hormone ghrelin play a role in several diseases related with inflammation. Although visfatin is a pro-inflammatory adipokine, ghrelin mainly exerts anti-inflammatory effects. However, very little is known about the role of visfatin and ghrelin in asthma. In the present study, we aimed to investigate the role of visfatin and ghrelin in asthma by evaluating their serum levels in asthmatic patients. MATERIALS AND METHODS: This study was performed on 27 asthma and 23 healthy controls. Blood samples were collected in tubes without EDTA. Serum levels of visfatin and ghrelin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program and differences were considered statistically significant at p < 0.05. RESULTS: Serum levels of visfatin and ghrelin were significantly higher in asthma group (respectively; p = 0.001, p = 0.002). CONCLUSION: While visfatin has a pro-inflammatory role, ghrelin exerts an anti-inflammatory effect in asthma. Therefore, visfatin can be a forthcoming biomarker and ghrelin may be a new anti-inflammatory drug target to diagnose and treat asthmatic patients.
Authors: Mohammed Saeed Al-Ayed; Khaled Sadeq Al-Shaibari; Dhafer Alshehri; Mohammed Jamaan Alzahrani; Iman Nasser; Hamdan Saad Alaamri; Wed Ahmad Alaseeri; Ahmed A Mahfouz; Saeed Ali Alsareii; Ahmed Morad Asaad; Aamir Magzoub; Mohammed Ansar Qureshi; Ehab Elagab; Elhashimi Eltayb Hassan; Mohammed Helmy Faris Shalayel Journal: Int J Environ Res Public Health Date: 2020-03-04 Impact factor: 3.390